CRLF2 Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
IGH::CRLF2 Fusion	Ruxolitinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID8540 To investigate the therapeutic potential of JAK inhibitors in Ph-like ALL, the authors examined the efficacy of ruxolitinib in murine xenograft models of 8 pediatric B-ALL cases. Six xenografts (I to … (full text at CIViC) PMID 22955920 · Maude et al., 2012 · Open in CIViC	civic
Adult B Acute Lymphoblastic Leukemia1
IGH::CRLF2 Fusion	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID7212 CRLF2 overexpression was examined in 90 adult B-ALL patients with demographic data that lacked characteristic rearrangements and identified overexpression in 15/90 (16.67%). Disease-free survival was … (full text at CIViC)

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Acute Lymphoblastic Leukemia1

IGH::CRLF2 Fusion

Ruxolitinib

Predictive

Supports Sensitivity Response

submitted

EID8540

To investigate the therapeutic potential of JAK inhibitors in Ph-like ALL, the authors examined the efficacy of ruxolitinib in murine xenograft models of 8 pediatric B-ALL cases. Six xenografts (I to … (full text at CIViC)

PMID 22955920 · Maude et al., 2012 · Open in CIViC

civic

Adult B Acute Lymphoblastic Leukemia1

IGH::CRLF2 Fusion

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID7212

CRLF2 overexpression was examined in 90 adult B-ALL patients with demographic data that lacked characteristic rearrangements and identified overexpression in 15/90 (16.67%). Disease-free survival was … (full text at CIViC)

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like3
IGH::CRLF2 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	5	accepted	EID11613 The authors performed genomic profiling of 1725 cases of B-lymphoblastic leukemia/lymphoma (B-ALL). Overall, 264 of 1725 B-ALL cases (15.3%) were identified as BCR::ABL1 (Ph)-like based on their expr… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic
IGH::CRLF2 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	4	accepted	EID8233 Among 284 cases with Ph-like expression signature who were identified by testing 1389 high-risk cases of pediatric B-ALL, overexpression and rearrangement of CRLF2 were identified in 124 (43.7%). This… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC	civic
IGH::CRLF2 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	2	accepted	EID11621 B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 2 patients (ages 7.6 and 16.3 yea… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like3

IGH::CRLF2 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11613

The authors performed genomic profiling of 1725 cases of B-lymphoblastic leukemia/lymphoma (B-ALL). Overall, 264 of 1725 B-ALL cases (15.3%) were identified as BCR::ABL1 (Ph)-like based on their expr… (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

civic

IGH::CRLF2 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID8233

Among 284 cases with Ph-like expression signature who were identified by testing 1389 high-risk cases of pediatric B-ALL, overexpression and rearrangement of CRLF2 were identified in 124 (43.7%). This… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

civic

IGH::CRLF2 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID11621

B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 2 patients (ages 7.6 and 16.3 yea… (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

civic

B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL11
IGH::CRLF2 Fusion AND JAK2 R683G	Sirolimus	Predictive	D	Supports Sensitivity Response	3	submitted	EID7641 Xenografts were established from Ph-like ALL patient derived cells harboring CRLF2 rearrangements and JAK2 mutations. A xenograft with a JAK2 R683G mutation and IGH-CRLF2 rearrangement showed signific… (full text at CIViC) PMID 22955920 · Maude et al., 2012 · Open in CIViC	civic

B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL11

IGH::CRLF2 Fusion AND JAK2 R683G

Sirolimus

Predictive

Supports Sensitivity Response

submitted

EID7641

Xenografts were established from Ph-like ALL patient derived cells harboring CRLF2 rearrangements and JAK2 mutations. A xenograft with a JAK2 R683G mutation and IGH-CRLF2 rearrangement showed signific… (full text at CIViC)

PMID 22955920 · Maude et al., 2012 · Open in CIViC

civic

Childhood B-cell Acute Lymphoblastic Leukemia2unmapped disease
IGH::CRLF2 Fusion	(prognostic)	Prognostic	B	Supports Poor Outcome	5	accepted	EID7238 Gene expression profiling of 207 uniformly treated children with high-risk B-progenitor acute lymphoblastic leukemia enrolled in COG P9906 study identified 29/207 (14%) with increased expression of CR… (full text at CIViC) PMID 20139093 · Harvey et al., 2010 · Open in CIViC	civic
IGH::CRLF2 Fusion	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	submitted	EID7240 Gene expression profiling of 207 uniformly treated children with high-risk B-progenitor acute lymphoblastic leukemia enrolled in COG P9906 study identified 29/207 (14%) with increased expression of CR… (full text at CIViC) PMID 20139093 · Harvey et al., 2010 · Open in CIViC	civic

Childhood B-cell Acute Lymphoblastic Leukemia2unmapped disease

IGH::CRLF2 Fusion

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID7238

Gene expression profiling of 207 uniformly treated children with high-risk B-progenitor acute lymphoblastic leukemia enrolled in COG P9906 study identified 29/207 (14%) with increased expression of CR… (full text at CIViC)

PMID 20139093 · Harvey et al., 2010 · Open in CIViC

civic

IGH::CRLF2 Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID7240

PMID 20139093 · Harvey et al., 2010 · Open in CIViC

civic

Unmapped disease1unmapped disease
IGH::CRLF2 Fusion	(functional)	Functional	D	Supports Gain Of Function	4	submitted	EID7214 Authors identified overexpression of CRLF2 arises from a translocation juxtaposing CRLF2 to the IGH promoter or an interstitial deletion of the PAR1 region. They hypothesize the PAR1 deletion can plac… (full text at CIViC) PMID 19641190 · Russell et al., 2009 · Open in CIViC	civic

Unmapped disease1unmapped disease

IGH::CRLF2 Fusion

(functional)

Functional

Supports Gain Of Function

submitted

EID7214

Authors identified overexpression of CRLF2 arises from a translocation juxtaposing CRLF2 to the IGH promoter or an interstitial deletion of the PAR1 region. They hypothesize the PAR1 deletion can plac… (full text at CIViC)

PMID 19641190 · Russell et al., 2009 · Open in CIViC

civic

Evidence by cancer (9 items)

Clinical significance (0)